Search Clinical Trials
By Condition
By Location (USA)
By Location (Other)
By Sponsor
Resources
Privacy Policy
About Us
Disclaimer
Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination with Gemcitabine and Cisplatin in Advanced Cancer Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination with Gemcitabine and Cisplatin in Advanced Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination with Gemcitabine and Cisplatin in Advanced Cancer Clinical research trials and Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination with Gemcitabine and Cisplatin in Advanced Cancer healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination with Gemcitabine and Cisplatin in Advanced Cancer. Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination with Gemcitabine and Cisplatin in Advanced Cancer Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination with Gemcitabine and Cisplatin in Advanced Cancer clinical trial. Human subjects often obtain the finest healthcare possible for their Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination with Gemcitabine and Cisplatin in Advanced Cancer condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.

Home > "S" Clinical Trials Conditions > Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination with Gemcitabine and Cisplatin in Advanced Cancer

Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination with Gemcitabine and Cisplatin in Advanced Cancer



Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination with Gemcitabine and Cisplatin in Advanced Cancer

For Condition: Neoplasms
Status: Suspended
Sponsor(s): Schering-Plough ,
Synopsis: The purpose of this study is to determine the safety and tolerability of an oral Farnesyl Protein Transferase Inhibitor (SCH 66336) when given in combination with Gemcitabine and Cisplatin in patients with advanced cancer
Details:
Eligibility:
Study Type:
  Interventional, Treatment, Non-Randomized, Open Label, Dose Comparison, Parallel Assignment, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Advanced cancer for which there is no treatment available which would have a reasonable chance of disease palliation or cure - Age greater than or equal to 18. - SWOG performance Status less than or equal to 2. - Meets protocol requirements for specified laboratory values. - Written informed consent and cooperation of patient. Exclusion Criteria: - Prior treatment with an FPTI - Knowledge of intracranial metastases or carcinomatous meningitis. - Poor medical risks because of nonmalignant systemic disease or uncontrolled active infection. - Medical conditions that would interfere with taking oral medications. - Significant uncontrolled diarrhea. - Chemotherapy, radiotherapy or major surgery within 4 weeks; full recovery from prior treatment. - Concomitant use of CYP3A inhibitors/inducers per protocol. - Known HIV positivity or AIDS-related illness. - Pregnant or nursing women. - Men or women of childbearing potential who are not using an effective method of contraception. - Concurrent chemotherapy, hormonal therapy, radiotherapy or immunotherapy. - QTc prolongation (>440 msecs) at baseline. - Patients with previous high-dose therapy requiring stem cell rescue or bone marrow transplant, or irradiation to >30% of bone marrow-containing areas. - Patients that have received Mitomycin-C or nitrosoureas.
Total Enrollment: 24

Location and Contact Information:

Anschutz Cancer Pavilion
Aurora,  Colorado, 
United States
 


Additional Information:
Study ID Numbers:
  P01499; 
Study Start Date: January 2001
Record last reviewed: September 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00040534

Other Neoplasms Studies:
1. Harvesting Cells for Experimental Cancer Treatments

2. MG98 in Treating Patients With Advanced Solid Tumors

3. Study to Determine Maximum Tolerated Dose of LErafAON Combined with Radiotherapy in Patients with Advanced Malignancies

4. Outpatient Treatment Of Deep Venous Thrombosis (DVT) Using Subcutaneous Dalteparin (Fragmin) In Low Risk Cancer Patients

5. Radiation Therapy and the Natural History of Childhood Cancers

Related Studies:

Other Neoplasms Clinical Trials
Other Colorado Clinical Trials
Other Aurora Clinical Trials

Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination with Gemcitabine and Cisplatin in Advanced Cancer

Modify your Search

  Other Neoplasms Clinical Trials
  Other Colorado Clinical Trials
  Other Aurora Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103